4.Development of colonic stent simulator using three-dimensional printing technique: a simulator development study in Korea
Hyundam GU ; Suyoung LEE ; Sol KIM ; Hye-Lim JANG ; Da-Woon CHOI ; Kyu Seok KIM ; Yu Ri SHIN ; Dae Young CHEUNG ; Bo-In LEE ; Jin Il KIM ; Han Hee LEE
Clinical Endoscopy 2024;57(6):790-797
Background/Aims:
Colonic stenting plays a vital role in the management of acute malignant colonic obstruction. The increasing use of self-expandable metal stents (SEMS) and the diverse challenges posed by colonic obstruction at various locations underscore the importance of effective training for colonic stent placement.
Methods:
All the components of the simulator were manufactured using silicone molding techniques in conjunction with three-dimensional (3D) printing. 3D images sourced from computed tomography scans and colonoscopy images were converted into a stereolithography format. Acrylonitrile butadiene styrene copolymers have been used in fused deposition modeling to produce moldings.
Results:
The simulator replicated the large intestine from the rectum to the cecum, mimicking the texture and shape of the human colon. It enables training for colonoscopy insertion, cecum intubation, loop reduction, and stenting within stenotic areas. Interchangeable stenotic modules for four sites (rectum, sigmoid colon, descending colon, and ascending colon) were easily assembled for training. These modules integrate tumor contours and blood vessel structures with a translucent center, allowing real-time visualization during stenting. Successful and repeatable demonstrations of stent insertion and expansion using the reusable SEMS were consistently achieved.
Conclusions
This innovative simulator offers a secure colonic stenting practice across various locations, potentially enhancing clinical outcomes by improving operator proficiency during actual procedures.
5.Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer:a cross-sectional survey
Ji Hyun KIM ; Yumi LEE ; Da-Young KIM ; Sinae KIM ; Sang-Soo SEO ; Sokbom KANG ; Sang-Yoon PARK ; Myong Cheol LIM
Journal of Gynecologic Oncology 2024;35(1):e3-
Objective:
To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution.
Methods:
The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence.
Results:
Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors.In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528–15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283–8.940; p=0.014), and a lower score on the quality-oflife assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027–1.086; p<0.001) were associated with high adherence to PARP inhibitors.
Conclusion
Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.
6.Development of colonic stent simulator using three-dimensional printing technique: a simulator development study in Korea
Hyundam GU ; Suyoung LEE ; Sol KIM ; Hye-Lim JANG ; Da-Woon CHOI ; Kyu Seok KIM ; Yu Ri SHIN ; Dae Young CHEUNG ; Bo-In LEE ; Jin Il KIM ; Han Hee LEE
Clinical Endoscopy 2024;57(6):790-797
Background/Aims:
Colonic stenting plays a vital role in the management of acute malignant colonic obstruction. The increasing use of self-expandable metal stents (SEMS) and the diverse challenges posed by colonic obstruction at various locations underscore the importance of effective training for colonic stent placement.
Methods:
All the components of the simulator were manufactured using silicone molding techniques in conjunction with three-dimensional (3D) printing. 3D images sourced from computed tomography scans and colonoscopy images were converted into a stereolithography format. Acrylonitrile butadiene styrene copolymers have been used in fused deposition modeling to produce moldings.
Results:
The simulator replicated the large intestine from the rectum to the cecum, mimicking the texture and shape of the human colon. It enables training for colonoscopy insertion, cecum intubation, loop reduction, and stenting within stenotic areas. Interchangeable stenotic modules for four sites (rectum, sigmoid colon, descending colon, and ascending colon) were easily assembled for training. These modules integrate tumor contours and blood vessel structures with a translucent center, allowing real-time visualization during stenting. Successful and repeatable demonstrations of stent insertion and expansion using the reusable SEMS were consistently achieved.
Conclusions
This innovative simulator offers a secure colonic stenting practice across various locations, potentially enhancing clinical outcomes by improving operator proficiency during actual procedures.
7.Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer:a cross-sectional survey
Ji Hyun KIM ; Yumi LEE ; Da-Young KIM ; Sinae KIM ; Sang-Soo SEO ; Sokbom KANG ; Sang-Yoon PARK ; Myong Cheol LIM
Journal of Gynecologic Oncology 2024;35(1):e3-
Objective:
To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution.
Methods:
The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence.
Results:
Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors.In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528–15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283–8.940; p=0.014), and a lower score on the quality-oflife assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027–1.086; p<0.001) were associated with high adherence to PARP inhibitors.
Conclusion
Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.
8.Development of colonic stent simulator using three-dimensional printing technique: a simulator development study in Korea
Hyundam GU ; Suyoung LEE ; Sol KIM ; Hye-Lim JANG ; Da-Woon CHOI ; Kyu Seok KIM ; Yu Ri SHIN ; Dae Young CHEUNG ; Bo-In LEE ; Jin Il KIM ; Han Hee LEE
Clinical Endoscopy 2024;57(6):790-797
Background/Aims:
Colonic stenting plays a vital role in the management of acute malignant colonic obstruction. The increasing use of self-expandable metal stents (SEMS) and the diverse challenges posed by colonic obstruction at various locations underscore the importance of effective training for colonic stent placement.
Methods:
All the components of the simulator were manufactured using silicone molding techniques in conjunction with three-dimensional (3D) printing. 3D images sourced from computed tomography scans and colonoscopy images were converted into a stereolithography format. Acrylonitrile butadiene styrene copolymers have been used in fused deposition modeling to produce moldings.
Results:
The simulator replicated the large intestine from the rectum to the cecum, mimicking the texture and shape of the human colon. It enables training for colonoscopy insertion, cecum intubation, loop reduction, and stenting within stenotic areas. Interchangeable stenotic modules for four sites (rectum, sigmoid colon, descending colon, and ascending colon) were easily assembled for training. These modules integrate tumor contours and blood vessel structures with a translucent center, allowing real-time visualization during stenting. Successful and repeatable demonstrations of stent insertion and expansion using the reusable SEMS were consistently achieved.
Conclusions
This innovative simulator offers a secure colonic stenting practice across various locations, potentially enhancing clinical outcomes by improving operator proficiency during actual procedures.
9.Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer:a cross-sectional survey
Ji Hyun KIM ; Yumi LEE ; Da-Young KIM ; Sinae KIM ; Sang-Soo SEO ; Sokbom KANG ; Sang-Yoon PARK ; Myong Cheol LIM
Journal of Gynecologic Oncology 2024;35(1):e3-
Objective:
To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution.
Methods:
The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence.
Results:
Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors.In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528–15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283–8.940; p=0.014), and a lower score on the quality-oflife assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027–1.086; p<0.001) were associated with high adherence to PARP inhibitors.
Conclusion
Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.
10.Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)
Ho-Jin SHIN ; Do-Young KIM ; Kihyun KIM ; Chang-Ki MIN ; Je-Jung LEE ; Yeung-Chul MUN ; Won-Sik LEE ; Sung-Nam LIM ; Jin Seok KIM ; Joon Ho MOON ; Da Jung KIM ; Soo-Mee BANG ; Jong-Ho WON ; Jae-Cheol JO ; Young Il KOH
Cancer Research and Treatment 2024;56(3):956-966
Purpose:
The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM.
Materials and Methods:
Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry.
Results:
The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines.
Conclusion
AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.

Result Analysis
Print
Save
E-mail